In early March, we surveyed the GO2 community to understand how recent federal executive orders are affecting patients, loved ones, healthcare providers, and researchers. Themes from 239 completed surveys covered 4 key areas: Impact on daily life or work [...]
Question: I’d like to start looking at whether a clinical trial might be good for me, but the process seems overwhelming. Where should I start? What are the best resources for me to understand my options? Answer: Whenever you [...]
A statement from GO2 President and CEO Laurie Ambrose I remember the day vividly in 2008. I succeeded in organizing a meeting with the Chairman of the House Appropriations Defense Subcommittee, Congressman John Murtha, to discuss establishing a dedicated [...]
WASHINGTON, March 25, 2025 — GO2 for Lung Cancer (GO2) announced it established the Global Advisory Council (GAC), a new group that brings together scientists, medical specialists, and other healthcare professionals from diverse disciplines who focus on GO2’s areas of impact: [...]
By Chaya Estrin-Lebovic, MPH, CHES, Registry Coordinator; John Wells MBA-HA, PMP, CSSGB, Manager Lung Cancer Registry; Courtney Granville, PhD, MSPH, Chief Scientific Officer Everyone living with lung cancer has unique experiences. Some people discover it unexpectedly—like the young mother [...]
GO2 for Lung Cancer stands alongside patients, families, healthcare providers, researchers, and the broader medical community in our mission to increase survival for those at risk, diagnosed, and living with lung cancer. On January 27, 2025, the Office of [...]
Goldwyn highlights the power of early detection to increase lung cancer survivorship WASHINGTON, Jan. 28, 2025 — GO2 for Lung Cancer launched a new awareness campaign to educate the public on the importance of screening for those at risk for [...]
On December 27, 2024, the U.S. Food and Drug Administration (FDA) approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Opdivo (nivolumab) that the FDA previously approved [...]
Aurora was diagnosed with stage 3 (III) EGFR lung cancer in 2021 when she was 28 years old. Having immigrated from the Philippines, her doctors thought that she had tuberculosis or an infection. Given her young age, her doctor [...]
On Dec. 18, 2024, the U.S. Food and Drug Administration (FDA) approved Ensacove (ensartinib) for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have an ALK mutation and have not previously received an ALK-targeted therapy. [...]